Skip to main content
OpenTrials
Recruiting

NCT Number: NCT01218776

International Survey of Acute Coronary Syndromes

The International Registry of Acute Coronary Syndromes registry study (ISACS) is both a retrospective and prospective study which was designed in order to obtain data of patients with acute coronary syndromes, and herewith control and optimize internationally guideline-recommended therapies in these countries

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Acute Coronary Syndrome Angina Pectoris Angina, Unstable Cardiovascular Diseases Chest Pain Coronary Disease Heart Diseases Infarction Ischemia Myocardial Infarction Myocardial Ischemia Necrosis Neurologic Manifestations Pain Pathologic Processes Pathological Conditions, Signs and Symptoms Signs and Symptoms Unstable Angina Pectoris Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

Aims of this survey study are (1) documentation of the characteristics of all patients presenting to the ISACS centers with STEMI or NSTEMI (2) documentation of in-hospital outcome, and outcome rates at 6 month and 1 year, (3) documentation of invasive procedures and procedure-associated complications (4) documentation of therapeutic regimens and investigation conformity of treatment with already established guidelines.

Investigators:

ISACS Administrative Committee:

Raffaele Bugiardini (Italy-Principal Investigator) Lina Badimon (Spain) Olivia Manfrini (Italy- Project Coordinator) Edina Cenko (Italy-Center Coordinator)

Steering Committee:

Mirza Dilic (Bosnia and Herzegovina), Asen Goudev (Bulgaria), Davor Milicic (Croatia), Raffaele Bugiardini, Edina Cenko and Olivia Manfrini (Italy) Gani Bajraktari (Kosovo), Andrejs Erglis and Ilja Zakke (Latvia), Remigius Zaliunas and Olivija Gustiene (Lithuania), Sasko Kedev and Marija Vavlukis (North Macedonia), Mihail Popovici (Moldova), Maria Dorobantu (Romania), Zorana Vasiljevic (Serbia), Eva Goncalvesova and Martin Studenkan (Slovakia) , Alexander N. Parkhomenko (Ukraine) , Christopher P Gale (United Kingdom).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • acute coronary syndromes

Exclusion criteria

  • under age or not able to give informed consent

Treatment and study plan

Primary outcomes

  1. All causes mortality

    Time frame: 30 days, 6 months, 1 year

    All causes mortality

Secondary outcomes

  1. Cardiovascular mortality

    Time frame: 30 days, 6 months, 1 year

    Cardiovascular mortality

  2. Recurrent myocardial infarction

    Time frame: 30 days, 6 months, 1year

    Recurrent myocardial infarction

  3. Pharmacogenetic and cardiovascular genetic studies associated to clinical outcomes

    Time frame: 6 month, 1 year

    Pharmacogenetic and cardiovascular genetic studies associated to clinical outcomes

  4. Adherence to internationally guideline recommended therapies across the participating countries

    Time frame: discharge, 6 months, 1 year

    Adherence to internationally guideline recommended therapies across the participating

Study contacts

Contact information is provided by the study sponsor or research team.

Lina Badimon, MD

CONTACT

[email protected]

+34 670296741

Raffaele Bugiardini, MD

CONTACT

[email protected]

+39 335 5612962

Sponsors and collaborators

Lead sponsor

University of Bologna

Other

Registry information

Acronym: ISACS

Important dates

Study start
2010
Primary completion
2026
Study completion
2026
First posted
Oct 11, 2010
Registry last updated
Apr 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.